Melisi D - Search Results

1

Metastatic pancreatic cancer: Is there a light at the end of the tunnel?

Vaccaro V, Sperduti I, Vari S, Bria E, Melisi D, Garufi C, Nuzzo C, Scarpa A, Tortora G, Cognetti F, Reni M, Milella M. Vaccaro V, et al. Among authors: melisi d. World J Gastroenterol. 2015 Apr 28;21(16):4788-801. doi: 10.3748/wjg.v21.i16.4788. World J Gastroenterol. 2015. PMID: 25944992 Free PMC article. Review.

2

Angiogenesis: a target for cancer therapy.

Tortora G, Melisi D, Ciardiello F. Tortora G, et al. Among authors: melisi d. Curr Pharm Des. 2004;10(1):11-26. doi: 10.2174/1381612043453595. Curr Pharm Des. 2004. PMID: 14754402 Review.

3

Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments.

Melisi D, Troiani T, Damiano V, Tortora G, Ciardiello F. Melisi D, et al. Endocr Relat Cancer. 2004 Mar;11(1):51-68. doi: 10.1677/erc.0.0110051. Endocr Relat Cancer. 2004. PMID: 15027885 Review.

4

Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.

Melisi D, Caputo R, Damiano V, Bianco R, Veneziani BM, Bianco AR, De Placido S, Ciardiello F, Tortora G. Melisi D, et al. Endocr Relat Cancer. 2005 Dec;12(4):1051-8. doi: 10.1677/erc.1.01061. Endocr Relat Cancer. 2005. PMID: 16322342

5

Key cancer cell signal transduction pathways as therapeutic targets.

Bianco R, Melisi D, Ciardiello F, Tortora G. Bianco R, et al. Among authors: melisi d. Eur J Cancer. 2006 Feb;42(3):290-4. doi: 10.1016/j.ejca.2005.07.034. Epub 2006 Jan 11. Eur J Cancer. 2006. PMID: 16376541 Review.

6

LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.

Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ. Melisi D, et al. Mol Cancer Ther. 2008 Apr;7(4):829-40. doi: 10.1158/1535-7163.MCT-07-0337. Mol Cancer Ther. 2008. PMID: 18413796 Free PMC article.

7

Emerging pathways and future targets for the molecular therapy of pancreatic cancer.

Vaccaro V, Melisi D, Bria E, Cuppone F, Ciuffreda L, Pino MS, Gelibter A, Tortora G, Cognetti F, Milella M. Vaccaro V, et al. Among authors: melisi d. Expert Opin Ther Targets. 2011 Oct;15(10):1183-96. doi: 10.1517/14728222.2011.607438. Epub 2011 Aug 7. Expert Opin Ther Targets. 2011. PMID: 21819318 Review.

8

Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.

Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T, Agrawal S, Di Nicolantonio F, Scarpa A, Bardelli A, Tortora G. Rosa R, et al. Among authors: melisi d. Clin Cancer Res. 2011 Oct 15;17(20):6531-41. doi: 10.1158/1078-0432.CCR-10-3376. Epub 2011 Sep 2. Clin Cancer Res. 2011. PMID: 21890455

9

Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy.

Tamburrino A, Piro G, Carbone C, Tortora G, Melisi D. Tamburrino A, et al. Among authors: melisi d. Front Pharmacol. 2013 Apr 30;4:56. doi: 10.3389/fphar.2013.00056. eCollection 2013. Front Pharmacol. 2013. PMID: 23641216 Free PMC article.

10

Rationale and clinical use of multitargeting anticancer agents.

Melisi D, Piro G, Tamburrino A, Carbone C, Tortora G. Melisi D, et al. Curr Opin Pharmacol. 2013 Aug;13(4):536-42. doi: 10.1016/j.coph.2013.06.012. Epub 2013 Jul 13. Curr Opin Pharmacol. 2013. PMID: 23856428 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

144 results

Search Page